ZG033 / HankeMab - LARVOL DELTA

A novel CD137 agonist exhibits potent antitumor efficacy with a good safety profile (AACR 2023) - "These data demonstrate that ZG033 is an FcγR crosslinking-dependent CD137 agonist that displays a favorable safety profile and has potential in either mono- or combinational immunotherapies."

Clinical • IO biomarker • Oncology • IFNG • NF-κβ • TNFA

ZG033, a novel CD137 agonist, induces superior anti-tumor activity without hepatotoxicity rely on Fc-mediated crosslinking (SITC 2022) - "The results in 5-week I.V. repeated-dose (3, 10 and 30 mg/kg) and single-dose toxicity studies (60 and 180 mg/kg) suggested that ZG033 was well tolerated in cynomolgus monkeys with no abnormal hepatic or renal function and hematological index. Conclusions These data demonstrate that ZG033 acts as an FcγR crosslinking-dependent CD137 agonist that displays a favorable safety profile and has potential in either mono- or combinational immunotherapies."

IO biomarker • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • IFNG • TNFA